Parker Institute for Cancer Immunotherapy Unveils 100+ Research Findings at AACR 2026
Event summary
- Parker Institute for Cancer Immunotherapy (PICI) presenting nearly 100 research findings at AACR Annual Meeting 2026 in San Diego.
- PICI unveiling largest plasma proteomics study (RADIOHEAD cohort) and new methylation-based tumor monitoring tools.
- Antoni Ribas, Director of PICI Center at UCLA, awarded 2026 AACR-Margaret Foti Award for Leadership in Cancer Research.
- Kristen Dahlgren, PICI's Chief of External Affairs, co-chairing AACR 2026 Annual Meeting Program Committee.
The big picture
The Parker Institute for Cancer Immunotherapy's extensive presence at AACR 2026 underscores its role as a key player in advancing cancer immunotherapy. With nearly 100 research contributions, PICI is demonstrating the power of its network model to drive innovation across cell therapies, resistance mechanisms, and precision platforms. The recognition of Antoni Ribas with the AACR-Margaret Foti Award further solidifies PICI's leadership position in the field.
What we're watching
- Research Translation
- How PICI's collaborative model will accelerate the transition from discovery to commercialization of cancer therapies.
- Technological Breakthroughs
- Whether the RADIOHEAD cohort's plasma proteomics findings will lead to more precise immunotherapy approaches.
- Industry Leadership
- The pace at which PICI can maintain its position at the forefront of cancer immunotherapy innovation.
Related topics